Clinical data | |||
---|---|---|---|
Routes of administration | Oral | ||
ATC code |
| ||
Identifiers | |||
| |||
CAS Number | |||
PubChem CID | |||
ChemSpider | |||
UNII | |||
KEGG | |||
ChEMBL | |||
PDB ligand | |||
Chemical and physical data | |||
Formula | C30H24N8O2 | ||
Molar mass | 528.576 g·mol−1 | ||
3D model ( JSmol) | |||
| |||
|
Eganelisib ( USAN), codenamed IPI-549, is an experimental drug being investigated as a possible treatment for cancer. It is a highly selective phosphoinositide 3-kinase inhibitor, and thus works by inhibiting the enzyme PIK3CG, disrupting the PI3K/AKT/mTOR signaling pathway which plays important roles in the development of cancer. [1]
Eganelisib is being developed by Infinity Pharmaceuticals. Early clinical trial results were published in September 2016. [2] On September 29, 2020, it was granted Fast Track designation by the United States Food and Drug Administration (FDA) as a treatment for inoperable, locally advanced, or metastatic triple-negative breast cancer, combined with a checkpoint inhibitor and chemotherapy. [3]
As of October 2020 [update], five phase I/II clinical trials were ongoing in the United States, and one in Europe. [4]
Clinical data | |||
---|---|---|---|
Routes of administration | Oral | ||
ATC code |
| ||
Identifiers | |||
| |||
CAS Number | |||
PubChem CID | |||
ChemSpider | |||
UNII | |||
KEGG | |||
ChEMBL | |||
PDB ligand | |||
Chemical and physical data | |||
Formula | C30H24N8O2 | ||
Molar mass | 528.576 g·mol−1 | ||
3D model ( JSmol) | |||
| |||
|
Eganelisib ( USAN), codenamed IPI-549, is an experimental drug being investigated as a possible treatment for cancer. It is a highly selective phosphoinositide 3-kinase inhibitor, and thus works by inhibiting the enzyme PIK3CG, disrupting the PI3K/AKT/mTOR signaling pathway which plays important roles in the development of cancer. [1]
Eganelisib is being developed by Infinity Pharmaceuticals. Early clinical trial results were published in September 2016. [2] On September 29, 2020, it was granted Fast Track designation by the United States Food and Drug Administration (FDA) as a treatment for inoperable, locally advanced, or metastatic triple-negative breast cancer, combined with a checkpoint inhibitor and chemotherapy. [3]
As of October 2020 [update], five phase I/II clinical trials were ongoing in the United States, and one in Europe. [4]